CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

TOPLINE RESULTS OBTAINED FROM PHASE III CLINICAL TRIAL OF SECUKINUMAB INJECTION

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the topline results from the Phase III equivalence clinical trial of Secukinumab Injection (the "**Product**"), developed by the Company's subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., for the treatment of moderate to severe plaque psoriasis have been obtained.

Psoriasis is an immune-mediated, chronic, inflammatory and systemic disease. Currently, there are over 7 million patients with psoriasis in China. Fully human interleukin (IL)-17A ("**IL-17A**"), primarily produced by activated T cells, is a key mediator in the pathogenesis of psoriasis. Secukinumab can specifically bind to IL-17A and block the signal transduction of IL-17 receptors, thereby inhibiting psoriastic inflammation.

The Product is a fully human IgG1 monoclonal antibody drug developed by the Group and is a biosimilar to Secukinumab Injection (Cosentyx®). The approved indications of Cosentyx® in China include plaque psoriasis in patients aged 6 years and older, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, and its efficacy and safety have been widely recognized.

The Group has conducted the development of the Product in accordance with the relevant research guidelines for biosimilars and carried out a head-to-head equivalence study versus Cosentyx®. This study was a multi-center, randomised, double-blinded, parallel, positive-controlled Phase III equivalence clinical trial designed to demonstrate consistency of efficacy between the Product and Cosentyx®in patients with moderate to severe plaque psoriasis. Subjects with moderate to severe plaque psoriasis were enrolled and randomised 1:1 to receive either the investigational group (the Product) or the reference group (Cosentyx®) in this study. Its primary endpoint was the proportion of patients achieving a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 12.

This pivotal study met its pre-specified primary endpoint and delivered positive topline results. Statistical analyses demonstrated that the Product was clinically equivalent to Cosentyx®, with a favorable safety profile and no new or unexpected safety signals observed, giving it potential to meet the long-term safety requirements for patients. Detailed data from this study will be presented at upcoming academic conferences and published in peer-reviewed journals.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 18 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.